Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy

Daniel J. LandsburgAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USACorrespondence[email protected]

Sunita D. NastaAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

James N. GersonAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

Jakub SvobodaAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

Elise A. ChongAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

Stephen J. SchusterAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

Stefan K. BartaAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

Kyle W. RobinsonAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

Mitchell E. HughesAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

show all

References

Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma [clinical trial, phase I clinical trial, phase II multicenter study randomized controlled trial research support, Non-U.S. Gov't]. J Clin Oncol. 2020;38(2):155–165.
PubMed Web of Science ®Google Scholar
Cheson BD, Pfistner B, Juweid ME, International Harmonization Project on Lymphoma, et al. Revised response criteria for malignant lymphoma [practice guideline]. J Clin Oncol. 2007;25(5):579–586.
PubMed Web of Science ®Google Scholar
Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS) [clinical trial, phase II multicenter study randomized controlled trial]. Lancet Haematol. 2019;6(5):e254–e265.
PubMed Web of Science ®Google Scholar
Smith SD, Lopedote P, Samara Y, et al. Polatuzumab vedotin for relapsed/refractory aggressive B-cell lymphoma: a multicenter post-marketing analysis. Clin Lymphoma Myeloma Leuk. 2021;21(3):170–175.
PubMed Web of Science ®Google Scholar
Segman Y, Ribakovsky E, Avigdor A, et al. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience. Leuk Lymphoma. 2021;62(1):118–124.
PubMed Web of Science ®Google Scholar
Dimou M, Papageorgiou SG, Stavroyianni N, et al. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. Hematol Oncol. 2021;39(3):336–348.
PubMed Web of Science ®Google Scholar
Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [research support, Non-U.S. Gov't research support, N.I.H., extramural]. Blood. 2017;130(16):1800–1808.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date